A. Savransky

Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series.

Tocilizumab has been proposed as a third-line therapy for refractory autoimmune encephalitis; pediatric Latin American data remain limited. OBJECTIVE To evaluate the efficacy and safety of tocilizumab in pediatric patients with severe or refractory anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis. MATERIALS...

[Chronic immunomodulatory treatment in MOGAD: Experience in Latin America].

Treatment of MOGAD includes management of the acute episode and the use of chronic immunomodulatory therapy to prevent relapses and sequelae and, in selected cases, the use of chronic immunomodulatory therapy to prevent relapses and sequelae.

[Disease associated with anti-myelin oligodendrocyte glycoprotein (MOGAD)].

The disease associated with antibodies against myelin oligodendrocyte glycoprotein (MOGAD) is an inflammatory demyelinating disorder of the central nervous system, with acute disseminated encephalomyelitis in children, and optic neuritis and transverse myelitis more frequently observed in adults.

[Dystonia].

[Update guide on pediatric multiple sclerosis].

Evidence indicates that early initiation of high-efficacy disease-modifying therapies is associated with improved long-term outcomes.